Pharmaceutical
Health
Technology

Supernus Pharmaceuticals

$33.25
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.34 (-1.01%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell SUPN and other stocks, options, ETFs, and crypto commission-free!

About

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. Read More The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

Employees
448
Headquarters
Rockville, Maryland
Founded
2005
Market Cap
1.74B
Price-Earnings Ratio
17.48
Dividend Yield
0.00
Average Volume
655.01K
High Today
$33.77
Low Today
$33.03
Open Price
$33.15
Volume
167.05K
52 Week High
$61.25
52 Week Low
$30.05

Collections

Pharmaceutical
Health
Technology
US
North America

News

The Motley FoolMay 8

3 Top Value Stocks to Buy in May

Did anyone say sell in May and go away? I wouldn't do that. In fact, I'd consider any drop in stocks now an opportunity, especially if the growth stories of underlying companies are still intact. Even now, there's plenty of value hidden in some stocks that you could consider dipping your fingers into. Our Motley Fool contributors believe Supernus Pharmaceuticals (NASDAQ:SUPN), Iron Mountain (NYSE:IRM), and Party City (NYSE:PRTY) are three value stocks ripe for buying now. Here's why. A prove-it story Geo...

379
The Motley FoolMay 8

Supernus Pharmaceuticals Inc (SUPN) Q1 2019 Earnings Call Transcript

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Q1 2019 Earnings Call , 9:00 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good morning, ladies and gentlemen, and welcome to the Supernus Pharmaceuticals' First Quarter 2019 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. As a reminder, this conference call is be...

25
Seeking AlphaMay 8

Supernus Pharmaceuticals (SUPN) CEO, Jack Khattar on Q1 2019 Results - Earnings Call Transcript

Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) Q1 2019 Earnings Conference Call May 8, 2019 9:00 AM ET Company Participants Jack Khattar - President, Chief Executive Officer Greg Patrick - Chief Financial Officer Peter Vozzo - Investor Relations Conference Call Participants Ken Cacciatore - Cowen & Co. David Steinberg - Jefferies Nick Rubino - Stifel Patrick Trucchio - Berenberg Capital Mick Ingerman - Piper Jaffray Esther Hong - Janney Operator Good morning ladies and gentlemen and welcome to the...

16

Earnings

$0.27
$0.37
$0.47
$0.57
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
$0.47 per share
Actual
$0.34 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.